5 Comments

This is a great article, thank you for posting it!

Expand full comment
author

In Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020 Nov 27;370(6520):eabd4250. doi: 10.1126/science.abd4250. Cross reactivity to other CoV and reactivation of CMV and/or HSV-1 seemed to place the host at higher risk of hospitalization consistent with the 'early response' hypothesis (early spike IgG causing ADE and progression due to cross-priming).

Expand full comment
author

In a small trial where 20 individuals got the BCG vaccine and 20 got the placebo, who then received a trivalent influenza vaccine 14 days later, the antibody response to the 2009 A (H1N1) pandemic virus was higher and with a more rapid seroconversion in the those who got the BCG vaccine [Leentjens J et al, 2015]. This shows trained innate immunity can cross-prime adaptive immunity and is disconcerting as it could place elders at higher risk of death with SARS-CoV-2 infection due to ADE.

Expand full comment

Thank You, Dr. Laderoute, for more excellent context in a complicated issue.

Expand full comment
author

You are most welcome!

Expand full comment